Evidence map›Paper›PMID 41026270›Full record

ArticleJournal of clinical immunology2025

Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-γ Treatment Efficacy.

Yi-Xin Liao, Lu Xia, Ping Liu, Xin-Hua Li, Li-Pin Liu, Li Xu, Di Tian, Dong-Ling Shi, Xiao-Man Guo, Xue Mei and 9 more

Abstract read
In one paragraph

Article in Journal of clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yi-Xin LiaoScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Lu XiaTuberculosis Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Ping LiuTuberculosis Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Xin-Hua LiDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, Guangdong, China.
Li-Pin LiuDepartment of Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China.
Li XuScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Di TianScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Dong-Ling ShiScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Xiao-Man GuoDepartment of Clinical Microbiology, Hubei Center for Clinical Laboratory, 60 Dingziqiao Road, Wuhan, 430064, Hubei, China.
Xue MeiDepartment of Severe Hepatic Diseases, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Satoshi OkadaDepartment of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, 734-8551, Japan.
Ya-Bin LiuScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Fei-Fei WangKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xiao-Chuan WangDepartment of Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China.
Chen ZhaoScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Xiao-Hong FanDepartment of Respiratory, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Jin-Qiao SunDepartment of Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. jinqiaosun@fudan.edu.cn.
Tie-Fu LiuScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China. liutiefu@shphc.org.cn.
Yun LingScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China. yun.ling@shphc.org.cn.

Funding

National Natural Science Foundation of China 32070946National Natural Science Foundation of China 82001680National Natural Science Foundation of China 82072260Shanghai Public Health Clinical Center Scientific Research Foundation KY-GW-2022-16the Shanghai 2020 "Science and Technology Innovation Action Plan" Medical Innovation Research Special 20Z11900900The Shanghai Hospital Development Center Foundation SHDC12022121the Three-Year Action Plan (2023-2025), the Key Discipline Program on Public Health System Construction of Shanghai GWVI-11.1-15
6 · The paper itself

Abstract

backgroundThe CYBB gene encodes the gp91-phox protein, a critical component of the NADPH oxidase complex involved in pathogen clearance. Mutations in CYBB are associated with chronic granulomatous disease (CGD), leading to recurrent bacterial infections.

objectiveTo understand the genetic causes of Chinese CGD patients.

methodsExome sequencing was used to identify mutations in CGD patients' PBMCs, confirmed by Sanger sequencing. Neutrophil respiratory burst capacity was analyzed to correlate with clinical treatment efficacy.

resultsWe identified five CYBB mutations in six CGD patients from five unrelated Chinese families, including two novel mutations (c.1507A > G:p.T503A, c.1587_1605del:p.529_535del), two rare mutations without functional characterization (c.43A > G:p.I15V, c.125C > A:p.T42K), and one recently reported in a different ethnicity (c.252G > T:p.A84A). Our analysis revealed that these mutations had varying effects on CYBB expression, demonstrating that the synonymous c.252G > T mutation is indeed a splicing mutation, resulting in exon 3 deletion and minimal protein expression. Neutrophils from all patients exhibited defective mitogen-stimulated respiratory bursts. However, only neutrophils with the I15V mutation responded to interferon-γ (IFN-γ) treatment, significantly improving the respiratory capacity defect. Consistent with this, the patient with the I15V mutation showed clinical improvement after two weeks of IFN-γ and anti-bacterial co-treatment.

conclusionOur findings underscore the diverse effects of CYBB mutations on protein expression and function. More importantly, they suggest that assessing the IFN-γ-mediated potentiation of respiratory burst response in patient's neutrophils is an effective way to predict the therapeutic efficacy of IFN-γ in treating CGD cases, particularly those with non-tuberculous mycobacteria (NTM) and Mycobacterium tuberculosis (TB).

Indexed as

Granulomatous Disease, ChronicInterferon-gammaMutationNADPH Oxidase 2NeutrophilsAdolescentChildChild, PreschoolChinaEast Asian PeopleExome SequencingFemaleHumansInfantMaleRespiratory BurstCYBB protein, humanInterferon-gammaNADPH Oxidase 2Chronic granulomatous disease (CGD)CYBB mutationIFN-γNeutrophilsRespiratory burst

Identifiers

PMID41026270
PMCPMC12484266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.